Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Frazier Management
AddedFeb 13, 2024
UpdatedJul 16, 2026
Frazier Management

Frazier Management

Operating

Frazier Healthcare Partners: A dedicated healthcare private equity and venture capital firm for 25 years.

Location
Seattle, WA, US
Founded
1991
Firm
Compare
Portfolio
Employees
Website

Investments

CurveBeam
CurveBeam
Series B

Total Raised

$25M

Rounds

1

Series B$25MJanuary 2023
Metagenomi
Metagenomi
Series B

Total Raised

$457M

Rounds

7

Series B$175MJanuary 2022
Silence Therapeutics
Silence Therapeutics
Public

Total Raised

$248.7M

Rounds

6

Post Ipo Equity$20MNovember 2021
Radionetics Oncology
Radionetics Oncology
Series A

Total Raised

$82.5M

Rounds

2

Seed$30MOctober 2021
Gritstone bio
Gritstone bio
Public

Total Raised

$571.6M

Rounds

10

Post Ipo Equity$55MSeptember 2021
Alpine Immune Sciences
Alpine Immune Sciences
Acquired

Total Raised

$475.3M

Rounds

8

Post Ipo Equity$91MSeptember 2021
Post Ipo Equity$25MJanuary 2019
Sonoma Biotherapeutics
Sonoma Biotherapeutics
Series C

Total Raised

$365M

Rounds

4

Series B$265MAugust 2021
Crinetics Pharmaceuticals
Crinetics Pharmaceuticals
Public

Total Raised

$796M

Rounds

15

Post Ipo Equity$15MJuly 2021
Seraxis
Seraxis
Series C

Total Raised

$40M

Rounds

1

Series C$40MFebruary 2021
Aclaris Therapeutics
Aclaris Therapeutics
Public

Total Raised

$219.9M

Rounds

10

Post Ipo EquityJanuary 2021
Sutro Biopharma
Sutro Biopharma
Public

Total Raised

$561.6M

Rounds

12

Post Ipo Equity$144.9MDecember 2020
Inipharm
Inipharm
Public

Total Raised

$35M

Rounds

1

Series A$35MNovember 2020
MBX Biosciences
MBX Biosciences
Series B

Total Raised

$174.9M

Rounds

3

Series A$34.6MJuly 2020
Lassen Therapeutics
Lassen Therapeutics
Series B

Total Raised

$116M

Rounds

2

Series A$31MJune 2020
Dascena
Dascena
Series D

Total Raised

$50.4M

Rounds

4

Series B$50MApril 2020
Aspen Neuroscience
Aspen Neuroscience
Series D

Total Raised

$264M

Rounds

4

Series A$70MApril 2020
Molecular Templates
Molecular Templates
Public

Total Raised

$348.2M

Rounds

16

Post Ipo Debt$45MMarch 2020
Syndax Pharmaceuticals
Syndax Pharmaceuticals
Public

Total Raised

$803.6M

Rounds

16

Post Ipo Debt$30MJanuary 2020
Tarsus Pharmaceuticals
Tarsus Pharmaceuticals
Public

Total Raised

$410.6M

Rounds

6

Series B$60MJanuary 2020
Regenxbio
Regenxbio
Public

Total Raised

$638.2M

Rounds

10

Post Ipo EquityJanuary 2020
Arcutis Biotherapeutics
Arcutis Biotherapeutics
Public

Total Raised

$683.5M

Rounds

8

Series C$94.5MOctober 2019
Recida Therapeutics
Recida Therapeutics
Series A

Total Raised

$18.6M

Rounds

3

Series A$8.5MFebruary 2019
Sojournix
Sojournix
Series C

Total Raised

$70M

Rounds

3

Series C$44MJanuary 2019
Mirum Pharmaceuticals
Mirum Pharmaceuticals
Public

Total Raised

$497M

Rounds

5

Series A$120MNovember 2018